Group 1: Eli Lilly - Eli Lilly has submitted a new oral weight loss drug, orforglipron, for FDA approval, indicating a competitive edge in the weight loss medication market [1] - Participants switching from Novo Nordisk's Wegovy to orforglipron maintained most of their weight loss, with an average rebound of only 0.9 kg [1] Group 2: Fosun Pharma - Fosun Pharma's subsidiary has signed a collaboration agreement with Clavis Bio, which could yield up to $363 million in payments [2] - Clavis Bio will have exclusive global rights (excluding mainland China, Hong Kong, and Macau) for development, production, and commercialization of the selected targets [2] - Fosun Pharma will also gain a minority stake in a new project company established by Clavis Bio for this collaboration [2] Group 3: Baidu - Baidu has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [3] - The issuance and listing are subject to shareholder approval and regulatory approvals, with specific details yet to be finalized [3] Group 4: BeiGene - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, reflecting the company's commitment to innovation in drug development [4] - Dr. Wang has been with BeiGene since 2011 and has progressively taken on more responsibilities in R&D leadership [4] Group 5: Junshi Biosciences - Junshi Biosciences announced that major shareholder Shanghai Tanying plans to reduce its stake by up to 2%, equating to approximately 2,053,380 shares [5] - The reduction is scheduled between January 13, 2026, and April 10, 2026, despite the shareholder's long-term confidence in the company's prospects [5]

百济神州(06160)发布公告，2025年12月17日，经百济神州有限公司(以下简称"公司")董事会审议通过， 公司董事会同意聘任公司全球研发负责人汪来博士担任公司总裁，全球研发负责人。聘任生效后，汪来 博士担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等职 能。 ...

Core Viewpoint - BeiGene has appointed Dr. Wang Lai as the new President and Global Head of R&D, effective December 17, 2025, following approval by the company's board of directors [1] Group 1 - The board of directors of BeiGene has approved the appointment of Dr. Wang Lai [1] - Dr. Wang Lai will be responsible for managing the company's R&D, business development, and alliance management functions [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於聘任公司高 級管理人員的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年12月18日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (C ...

北京商报讯（记者 丁宁）12月18日晚间，百济神州（688235）发布公告称，12月17日，经公司董事会 审议通过，公司董事会同意聘任公司全球研发负责人汪来担任公司总裁，全球研发负责人。聘任生效 后，汪来担任公司总裁，全球研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理等 职能。 公告显示，汪来自2021年4月起担任百济神州全球研发负责人。在此之前，自2011年加入公司以来，他 担任过多个研发领导职务，职责逐渐扩大。加入公司之前，于2008年至2011年，汪来在位于美国德克萨 斯州达拉斯的生物技术公司Joyant Pharmaceuticals担任研究主管。汪来于1996年获得复旦大学理学学士 学位，于2001年获得德克萨斯大学圣安东尼奥健康科学中心博士学位。 ...

关于聘任公司高级管理人员的公告 A股代码：688235 A股简称：百济神州 公告编号：2025-042 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025 年 12 月 17 日，经百济神州有限公司（以下简称"公司"）董事 会审议通过，公司董事会同意聘任公司全球研发负责人汪来博士担任公 司总裁，全球研发负责人。聘任生效后，汪来博士担任公司总裁，全球 研发负责人职务，负责管理公司研发、业务拓展以及业务联盟关系管理 等职能。 特此公告。 百济神州有限公司董事会 附件：汪来博士的履历 汪来博士自 2021 年 4 月起担任公司全球研发负责人。在此之前，自 2011 年加入公司以来，他担任过多个研发领导职务，职责逐渐扩大。 加入公司之前，于 2008 年至 2011 年，汪来博士在位于美国德克萨斯 州达拉斯的生物技术公司 Joyant Pharmaceuticals 担任研究主管。汪来 博士于 1996 年获得复旦大学理学学士学位，于 2001 年获得德克萨斯 大学圣安东尼奥健康科学中心博士学位。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并 ...

Group 1 - The core point of the article is the appointment of Dr. Wang Lai as the new president and global head of R&D for BeiGene, which was approved by the company's board of directors [1] - For the year 2024, BeiGene's revenue composition is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [1] - As of the report, BeiGene's market capitalization stands at 418.6 billion yuan [1]

Core Insights - The biopharmaceutical sector in Guangzhou, particularly in the Huangpu District, is rapidly developing, with a focus on innovation in areas such as gene therapy, diagnostics, and medical devices [1][5][21] - Guangzhou has established itself as a hub for unicorn companies, with 210 enterprises listed, 60 of which are in Huangpu, representing 29% of the city's total [1][5] - The "Strategic Entrepreneur Cultivation Plan" initiated by the Guangzhou Development Zone aims to enhance the competitiveness of biopharmaceutical companies through resource integration and systematic training [1][5] Biopharmaceutical Industry Development - Huangpu District has over 4,800 biopharmaceutical companies, including 528 high-tech firms and 21 listed companies, accounting for 72% of the city's total [7][21] - The district's industrial output value reached 35.1 billion yuan, positioning it among the top tiers of China's biopharmaceutical industry [7] - The area has seen a significant increase in clinical trial approvals, with 115 new approvals in 2024, including 99 for innovative drugs [7][21] Key Companies and Innovations - Yunzhou Biotech has become the world's largest CRO service provider for research-grade gene vectors, delivering over one million gene vectors globally by 2024 [2][17] - The company has achieved a compound annual growth rate of over 20% in revenue over the past three years, with a valuation exceeding 70 billion yuan, making it the first biopharmaceutical unicorn in Guangzhou [17] - Other notable companies in the region include Akeso, BeiGene, and Hengrui Medicine, contributing to a diverse and innovative biopharmaceutical landscape [5][18] Strategic Initiatives and Collaborations - The Guangzhou International Bio-Island initiative aims to create a comprehensive biopharmaceutical ecosystem through the establishment of pilot parks that enhance collaboration among companies [9][10] - The Huangpu District has implemented multiple policies to support the biopharmaceutical industry, including the "Biopharmaceutical 3.0" policy, which focuses on technology innovation, product commercialization, and talent support [25][30] - Recent investments from global healthcare giants, such as the establishment of a production base by Medtronic, highlight the area's attractiveness for foreign investment [28][30]

Group 1 - The Hong Kong stock market has stabilized, maintaining a narrow range around the mid-axis during the morning session, with slight gains in consumer and technology sectors, while the internet and healthcare sectors experienced a downturn [1] - The consumer sector showed signs of recovery, with a slight increase of 0.32% by midday, driven by stocks such as Li Ning up 4.37%, Shenzhou International up 2.26%, and several others like Stone Pharmaceutical, Lao Pu Gold, WuXi Biologics, and Pop Mart all rising over 1% [3] - The technology sector also saw a minor increase of 0.14% by midday, with Meituan up 1.21%, while major players like JD Group, Alibaba, Tencent Holdings, and SMIC posted slight gains; however, BYD and NetEase faced minor declines [3] Group 2 - The healthcare sector had a lackluster performance, with Stone Pharmaceutical up 1.9% and WuXi Biologics up 1.68%, while other stocks like BeiGene, Innovent Biologics, and 3SBio saw slight increases; in contrast, companies like CanSino Biologics, China Biologic Products, JD Health, and Hansoh Pharmaceutical experienced minor declines [3]

Core Viewpoint - The domestic innovative pharmaceutical industry in China is transitioning from a "catch-up" phase to an "exceeding" phase, driven by ongoing drug review reforms, engineering talent, abundant clinical resources, and supportive policies [1] Group 1: Industry Trends - The number of clinical trials initiated by Chinese innovative drug companies has significantly increased, with Chinese firms now accounting for over 50% of global R&D projects [1] - The Hang Seng Biotechnology ETF by Fuguo Fund, which focuses on core pharmaceutical assets in Hong Kong, is set to close its fundraising on December 19 [1] Group 2: Index Characteristics - The Hang Seng Biotechnology Index emphasizes high-growth sectors such as innovative drugs and CXO (Contract Research Organization), with over 90% weight in these two areas [1] - The index employs a unique discount coefficient design, reducing the weight of drug distribution stocks to better reflect the growth potential of high R&D investment companies [1] - The index's quarterly rebalancing mechanism optimizes constituent stocks while maintaining stability and representativeness [1] Group 3: Performance Metrics - The top ten constituents of the Hang Seng Biotechnology Index include leading companies across the pharmaceutical value chain, such as WuXi Biologics and BeiGene [2] - The index has shown strong performance, with a year-to-date increase of 68.41% as of December 16, outperforming the Hang Seng Healthcare Index and the Hang Seng Index [2] - Since its inception on December 31, 2013, the index has achieved a cumulative increase of 45.19%, significantly surpassing the 9.37% increase of the Hang Seng Healthcare Index [2] - The current P/E ratio of the index is below 28, indicating attractive valuation compared to the 15.96% percentile over the past three years [2] Group 4: Fund Management - The proposed fund manager for the Hang Seng Biotechnology ETF is Cai Kaer, who has over 12 years of experience in securities and more than 8 years in investment management [3] - The quantitative investment team led by Dr. Li Xiaowei provides robust support for the fund's operations, having accumulated extensive experience in index quantitative investment [3] Group 5: Market Opportunities - The launch of the Hang Seng Biotechnology Index futures enhances liquidity and strategy diversity for related assets [3] - The ongoing development of China's biopharmaceutical industry, particularly since the 14th Five-Year Plan, presents significant market opportunities for innovative drug development [3]